Clinical Trials

178 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05446298 2025-07-29

PRESERVE-004

58 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05605535 2025-07-11

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

88 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05335993 2025-07-10

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

Phase 2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07044349 2025-06-30

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

72 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05032040 2025-02-07

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

170 enrolled

GenitourinaryGynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06014190 2024-08-29

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Phase 2 Recruiting

460 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

20 enrolled 42 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

19 enrolled 39 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT02033616 2022-04-25

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

Phase 2 Unknown

99 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Phase 2 Unknown

126 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04846842 2021-04-19

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Unknown

46 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01899599 2020-10-22

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

216 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00391118 2020-10-19

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

153 enrolled 20 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00479817 2019-12-18

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

161 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00721162 2019-09-26

Study of Ramucirumab in Ovarian Cancer

60 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01381861 2019-03-05

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

23 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

32 enrolled 12 charts